Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
Laura Sepp-Lorenzino, PhD
Former CSO
Intellia Therapeutics
Shengdar Tsai, PhD
Associate Member,
Department of Hematology
St. Jude Children’s Research Hospital
- Time:
Complex biologics such as bifunctional antibodies are opening new therapeutic possibilities in oncology, but these molecules present CRISPR is now a household term. Stories of genome editing therapies like Casgevy and Baby KJ have been headlines in our inboxes for years. Despite those cases, and the optimism they bring, genome editing has had significant challenges moving into the clinic.
This GEN Live show will bring together a panel of leading experts to break down the latest advances, innovations, and challenges shaping genome editing. The discussion will cover a lot of bases: CRISPR breakthroughs, emerging gene editing platforms, clinical trial milestones, regulatory shifts, access, off-target effects and safety considerations, and the growing role of large-scale population genomics in guiding precision therapies. Please join us to learn more and—because we plan to take questions from the audience—please bring your questions for our panelists, too!
Produced with support from:
The post Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
